Resorcinol: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Ammu Susheela (talk | contribs)
nocaptcha, Administrators
14,466 edits
No edit summary
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Protected "Resorcinol": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))
 
(9 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag={{Ammu}}
|authorTag={{Ammu}}
|OTC=Yes
|genericName=sulfur and resorcinol
|genericName=sulfur and resorcinol
|aOrAn=a
|aOrAn=an
|drugClass=anti acne agent
|drugClass=anti [[acne]] agent
|indicationType=treatment
|indicationType=treatment
|indication=management of acne
|indication=management of [[acne]]
 
|adverseReactions=[[hypersensitivity]]
|adverseReactions=<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Line 16: Line 16:


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
|fdaLIADAdult=* Uses for the management of [[acne]]
 
* Penetrates pores to control [[acne]] blemishes, [[acne]] pimples, blackheads and whiteheads
* Dosing Information
* Helps keep skin clear of new [[acne]] blemishes, [[acne]] pimples, blackheads and whiteheads.
 
=====Directions=====
:* Dosage
* Shake well
 
* Cleanse he skin thoroughly before applying the medication
=====Condition2=====
* Cover the entire affected area with a thin layer one to three times daily
 
* Because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor
* Dosing Information
* If bothersome dryness or peeling occurs, reduce application to once a day or every other day.
 
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.


<!--Off-Label Use and Dosage (Pediatric)-->
<!--Off-Label Use and Dosage (Pediatric)-->


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
|contraindications=* Condition1
|contraindications=<!--Warnings-->
 
|warnings=* For external use only
<!--Warnings-->
* Flammable, Keep away from fire or flame
|warnings=* Description
* Do not use on broken skin, on large areas of the body
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
=====Body as a Whole=====
=====Cardiovascular=====
=====Digestive=====
=====Endocrine=====
=====Hematologic and Lymphatic=====
=====Metabolic and Nutritional=====
=====Musculoskeletal=====
=====Neurologic=====
=====Respiratory=====
=====Skin and Hypersensitivy Reactions=====
=====Special Senses=====
=====Urogenital=====
=====Miscellaneous=====
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
|drugInteractions=<!--Use in Specific Populations-->
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
Line 268: Line 67:


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* Oral
|administration=* [[Topical]]
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Description


<!--IV Compatibility-->
<!--IV Compatibility-->
Line 279: Line 76:


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.


<!--Pharmacology-->
<!--Pharmacology-->


<!--Drug box 2-->
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|drugBox={{chembox2
|mechAction=*
| Verifiedfields = changed
 
| verifiedrevid = 415763656
<!--Structure-->
|  Name = Resorcinol
|structure=*
|  ImageFileL1 = Resorcinol.png
 
|  ImageNameL1 = Skeletal formula
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
|  ImageFileR1 = Resorcinol-3D-balls.png
 
|  ImageNameR1 = Ball-and-stick model
<!--Pharmacodynamics-->
|  IUPACName = Benzene-1,3-diol
|  OtherNames = Resorcin<br />m-dihydroxybenzene; 1,3-benzenediol; 1,3-Dihydroxybenzene; 3-Hydroxyphenol; m-hydroquinone; m-benzenediol; 3-hydroxycyclohexadien-1-one
| Section1 = {{Chembox Identifiers
|  ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 27810
| SMILES = c1cc(cc(c1)O)O
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4878
| PubChem = 5054
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 24147
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = YUL4LO94HK
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00133
| InChI = 1/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H
| InChIKey = GHMLBKRAJCXXBS-UHFFFAOYAB
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GHMLBKRAJCXXBS-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo = 108-46-3
| UNNumber = 2876
| ATCCode_prefix = D10
| ATCCode_suffix = AX02
| ATC_Supplemental = {{ATC|S01|AX06}}
  }}
| Section2 = {{Chembox Properties
|  Formula = C<sub>6</sub>H<sub>6</sub>O<sub>2</sub>
|   MolarMass = 110.1 g/mol
|  Appearance = White solid
|  Density = 1.28 g/cm<sup>3</sup>, solid
|  Solubility = 110 g/100 mL at 20 °C
|  MeltingPtC = 110
|  BoilingPtC = 277
|  pKa = 9.15<ref>Gawron, O., Duggan, M., Grelechi, C., ''J. Anal. Chem.'', '''1952''', ''24'', 969.</ref>
  }}
| Section3 = {{Chembox Structure
|  Dipole =
  }}
| Section7 = {{Chembox Hazards
|   ExternalMSDS =
|   FlashPtF = 261
|   EUClass = Harmful ('''Xn''')<br />Dangerous for<br />the environment ('''N''')
  }}
}}
|mechAction=<!--Structure-->
|structure=<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.


Line 317: Line 150:


<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|packLabel=[[File:Resorcinol 01.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]]
|packLabel=<!--Patient Counseling Information-->
[[File:Resorcinol 02.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


Line 325: Line 158:


<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title =  | url =  }}</ref>
|brandNames=* ACNOTEX ACNE TREATMENT®<ref>{{Cite web | title = ACNOTEX ACNE TREATMENT - sulfur and resorcinol lotion | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89bc8aff-8cd7-41ed-8619-11cd2dd5ffde }}</ref>


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
<!--Drug Shortage Status-->
|drugShortage=
|drugShortage=
}}
}}
{{LabelImage
 
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<!--Pill Image-->
<!--Pill Image-->


Line 352: Line 177:


[[Category:Drug]]
[[Category:Drug]]
[[Category:IARC Group 3 carcinogens]]

Latest revision as of 17:04, 20 August 2015

Resorcinol
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Overview

Resorcinol is an anti acne agent that is FDA approved for the treatment of management of acne. Common adverse reactions include hypersensitivity.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Uses for the management of acne
  • Penetrates pores to control acne blemishes, acne pimples, blackheads and whiteheads
  • Helps keep skin clear of new acne blemishes, acne pimples, blackheads and whiteheads.
Directions
  • Shake well
  • Cleanse he skin thoroughly before applying the medication
  • Cover the entire affected area with a thin layer one to three times daily
  • Because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor
  • If bothersome dryness or peeling occurs, reduce application to once a day or every other day.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Resorcinol in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Resorcinol in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Resorcinol in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Resorcinol in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Resorcinol in pediatric patients.

Contraindications

There is limited information regarding Resorcinol Contraindications in the drug label.

Warnings

  • For external use only
  • Flammable, Keep away from fire or flame
  • Do not use on broken skin, on large areas of the body

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Resorcinol in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Resorcinol in the drug label.

Drug Interactions

There is limited information regarding Resorcinol Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Resorcinol in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Resorcinol during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Resorcinol with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Resorcinol with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Resorcinol with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Resorcinol with respect to specific gender populations.

Race

There is no FDA guidance on the use of Resorcinol with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Resorcinol in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Resorcinol in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Resorcinol in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Resorcinol in patients who are immunocompromised.

Administration and Monitoring

Administration

Monitoring

There is limited information regarding Monitoring of Resorcinol in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Resorcinol in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Resorcinol in the drug label.

Pharmacology

Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox E numberTemplate:Chembox UNNumberTemplate:Chembox AppearanceTemplate:Chembox DensityTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox SolubilityInWaterTemplate:Chembox pKaTemplate:Chembox StructureTemplate:Chembox EUClassTemplate:Chembox FlashPtTemplate:Chembox Supplement
Template:Chembox header2 | Resorcinol
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
KEGG
UNII
Properties
C6H6O2
Molar mass 110.1 g/mol
Hazards
Template:Chembox header2 | Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Mechanism of Action

There is limited information regarding Resorcinol Mechanism of Action in the drug label.

Structure

There is limited information regarding Resorcinol Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Resorcinol in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Resorcinol in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Resorcinol in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Resorcinol in the drug label.

How Supplied

There is limited information regarding Resorcinol How Supplied in the drug label.

Storage

There is limited information regarding Resorcinol Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Resorcinol |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.

{{#ask: Label Page::Resorcinol |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Resorcinol in the drug label.

Precautions with Alcohol

  • Alcohol-Resorcinol interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • ACNOTEX ACNE TREATMENT®[2]

Look-Alike Drug Names

There is limited information regarding Resorcinol Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Gawron, O., Duggan, M., Grelechi, C., J. Anal. Chem., 1952, 24, 969.
  2. ↑ "ACNOTEX ACNE TREATMENT - sulfur and resorcinol lotion".
Retrieved from "https://www.wikidoc.org/index.php?title=Resorcinol&oldid=1137398"